Laminin subunit alpha-5 (LAMA5) mRNA (LAMA5 mRNA)

LAMA5 mRNA encodes the laminin alpha-5 chain, a large glycoprotein that serves as a primary component of the extracellular matrix. This transcript is translated into a protein that forms heterotrimeric laminins, such as laminin-511 and laminin-521, which are foundational to basement membranes in the kidney, lung, and vascular system (UniProt P57422). Biologically, LAMA5 is crucial for cell adhesion, migration, and the regulation of cellular phenotypes through interactions with integrin receptors (PubMed: 11018046). In various cancers, including breast and colorectal carcinoma, LAMA5 mRNA expression is frequently elevated, correlating with increased metastatic potential and poor patient prognosis (PubMed: 28652445). Targeting LAMA5 mRNA using antisense oligonucleotides or small interfering RNAs (siRNAs) is an emerging therapeutic strategy aimed at disrupting the tumor microenvironment and inhibiting angiogenesis. Beyond oncology, mutations in the LAMA5 gene are linked to Pierson syndrome, a condition characterized by congenital nephrotic syndrome and ocular abnormalities (PubMed: 15155759). Therapeutic challenges include the potential for severe off-target effects in healthy tissues, particularly the glomerular basement membrane, where LAMA5 is essential for filtration. Consequently, current research focuses on localized delivery or tumor-specific targeting to mitigate systemic toxicity.

Other names

LAMA5Laminin-10 subunit alphaLaminin-11 subunit alphaLaminin-15 subunit alphaLaminin subunit alpha-5

RNA interference or antisense inhibition of the LAMA5 transcript to prevent translation of the laminin alpha-5 protein and disrupt basement membrane-mediated signaling (PubMed: 28652445).